Miriam R. Elman

Miriam R. Elman

Auto-generated profile, based on publicly available information

Miriam R. Elman

School of Public Health, Oregon Health & Science University, Portland, OR, United States

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
CWCraig D. Williams
Craig D. Williams
ACAndrew T. Chan
Andrew T. Chan
MEMiriam R. Elman
Miriam R. Elman
AKAlyson H. Kristensen
Alyson H. Kristensen
WMW. Fred Miser
W. Fred Miser
JMJessina C. McGregor
Jessina C. McGregor

22 February 2013 in BMC Family Practice
Verified
Journal Article
Open access
PDF file
JMJessina C McGregor
Jessina C McGregor
MEMiriam R Elman
Miriam R Elman
DBDavid T Bearden
David T Bearden
DSDavid H Smith
David H Smith
Urinary tract infections (UTIs) are one of the most common infections treated in ambulatory care settings, however the epidemiology differs by age and sex. The incidence of UTI is far greater in females than males, and infection in pediatric patients is more often due to anatomical abnormalities. The purpose of this research was to describe age- and sex-specific trends in antibiotic susceptibility to common urinary anti-infectives among urinary isolates of Escherichia coli from ambulatory primary care patients in a regional health maintenance organization.

16 May 2023 in Journal of the American Heart Association
Verified
Journal Article
Closed access
AAAhmed M. Altibi
Ahmed M. Altibi
FGFares Ghanem
Fares Ghanem
YZYuanzi Zhao
Yuanzi Zhao
MEMiriam Elman
Miriam Elman
JCJoaquin Cigarroa
Joaquin Cigarroa
AMAhmad Masri
Ahmad Masri
Background: Prior national data showed a substantial in‐hospital mortality in septal myectomy (SM) with an inverse volume–outcomes relationship. This study sought to assess the contemporary outcomes of septal reduction therapy and volume–outcome relationship in obstructive hypertrophic cardiomyopathy. Methods and Results: All septal reduction therapy admissions between 2010 to 2019 in the United States were analyzed using the National Readmission Databases. Hospitals were stratified into tertiles of low‐, medium‐, and high‐volume based on annualized procedural volume of alcohol septal ablation and SM. Of 19 007 patients with obstructive hypertrophic cardiomyopathy who underwent septal reduction therapy, 12 065 (63%) had SM. Two‐thirds of hospitals performed ≤5 SM or alcohol septal ablation annually. In all SM encounters, 482 patients (4.0%) died in‐hospital post‐SM. In‐hospital mortality was <1% in 1505 (88.4%) hospitals, 1% to 10% in 30 (1.8%) hospitals, and ≥10% in 167 (9.8%) hospitals. There were 63 (3.7%) hospitals (averaging 2.2 SM cases/year) with 100% in‐hospital mortality. Post‐SM (in low‐, medium‐, and high‐volume centers, respectively), in‐hospital mortality (5.7% versus 3.9% versus 2.4%, P =0.003; adjusted odds ratio [aOR], 2.86 [95% CI, 1.70–4.80], P =0.001), adverse in‐hospital events (21.30% versus 18.0% versus 12.6%, P =0.001; aOR, 1.88 [95% CI, 1.45–2.43], P =0.001), and 30‐day readmission (17.1% versus 12.9% versus 9.7%, P =0.001; adjusted hazard ratio, 1.53 [95% CI, 1.27–1.96], P =0.001) were significantly higher in low‐ versus high‐volume hospitals. For alcohol septal ablation, the incidence of in‐hospital death and all other outcomes did not differ by hospital volume. Conclusions: In‐hospital SM mortality was 4% with an inverse volume‐mortality relationship. Mortality post‐alcohol septal ablation was similar across all volume tertiles. Morbidity associated with SM was substantial across all volume tertiles.

1 October 2021 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Open access
LFLaura E. Fischer
Laura E. Fischer
BWBruce M. Wolfe
Bruce M. Wolfe
NFNora Fino
Nora Fino
MEMiriam R. Elman
Miriam R. Elman
DFDavid R. Flum
David R. Flum
DKDavid E. Kleiner
David E. Kleiner
Postbariatric hypoglycemia (PBH) can be a devastating complication for which current therapies are often incompletely effective. More information is needed regarding frequency, incidence, and risk factors for PBH. To examine hypoglycemia symptoms following Roux-en-Y gastric bypass (RYGB) and laparoscopic adjustable gastric banding (LAGB) and baseline and in-study risk factors. Multicenter, at 10 US hospitals in 6 geographically diverse clinical centers. A prospective, longitudinal cohort study of adults undergoing RYGB or LAGB as part of clinical care between 2006 and 2009 were recruited and followed until January 31, 2015, with baseline and annual postoperative research assessments. We analyzed baseline prevalence and post-operative incidence and frequency of self-reported hypoglycemia symptoms as well as potential preoperative risk factors. In all groups, postoperative prevalence of hypoglycemia symptoms was 38.5%. Symptom prevalence increased postoperatively from 2.8%-36.4% after RYGB in patients without preoperative diabetes (T2D), with similar patterns in prediabetes (4.9%-29.1%). Individuals with T2D had higher baseline hypoglycemia symptoms (28.9%), increasing after RYGB (57.9%). Hypoglycemia symptoms were lower after LAGB, with 39.1% reported hypoglycemia symptoms at only 1 postoperative visit with few (4.0%) having persistent symptoms at 6 or more annual visits. Timing of symptoms was not restricted to the postprandial state. Symptoms of severe hypoglycemia were reported in 2.6-3.6% after RYGB. The dominant risk factor for postoperative symptoms was preoperative symptoms; additionally, baseline selective serotonin (SSRI) and serotonin-norepinephrine (SNRI) reuptake inhibitor use was also associated with increased risk in multivariable analysis. Weight loss and regain were not related to hypoglycemia symptom reporting. Hypoglycemia symptoms increase over time after RYGB, particularly in patients without diabetes. In a small percentage, symptoms can be persistent or severe and require hospitalization. Preoperative hypoglycemia symptoms and SSRI/SNRI use in RYGB patients without diabetes is associated with increased risk of symptoms.

1 September 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
JFJon P. Furuno
Jon P. Furuno
BNBrie N. Noble
Brie N. Noble
KHKristi N. Horne
Kristi N. Horne
JMJessina C. McGregor
Jessina C. McGregor
MEMiriam R. Elman
Miriam R. Elman
EFErik K. Fromme
Erik K. Fromme
The use of antibiotics is common in hospice care despite limited evidence that it improves symptoms or quality of life. Patients receiving antibiotics upon discharge from a hospital may be more likely to continue use following transition to hospice care despite a shift in the goals of care. We quantified the frequency and characteristics for receiving a prescription for antibiotics on discharge from acute care to hospice care. This was a cross-sectional study among adult inpatients (≥18 years old) discharged to hospice care from Oregon Health & Science University (OHSU) from 1 January 2010 to 31 December 2012. Data were collected from an electronic data repository and from the Department of Care Management. Among 62,792 discharges, 845 (1.3%) patients were discharged directly to hospice care (60.0% home and 40.0% inpatient). Most patients discharged to hospice were >65 years old (50.9%) and male (54.6%) and had stayed in the hospital for ≤7 days (56.6%). The prevalence of antibiotic prescription upon discharge to hospice was 21.1%. Among patients discharged with an antibiotic prescription, 70.8% had a documented infection during their index admission. Among documented infections, 40.3% were bloodstream infections, septicemia, or endocarditis, and 38.9% were pneumonia. Independent risk factors for receiving an antibiotic prescription were documented infection during the index admission (adjusted odds ratio [AOR] = 7.00; 95% confidence interval [95% CI] = 4.68 to 10.46), discharge to home hospice care (AOR = 2.86; 95% CI = 1.92 to 4.28), and having a cancer diagnosis (AOR = 2.19; 95% CI = 1.48 to 3.23). These data suggest that a high proportion of patients discharged from acute care to hospice care receive an antibiotic prescription upon discharge.

10 April 2013 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
PLPamela J Levine
Pamela J Levine
MEMiriam R Elman
Miriam R Elman
RKRavina Kullar
Ravina Kullar
JTJohn M Townes
John M Townes
DBDavid T Bearden
David T Bearden
JMJessina C McGregor
Jessina C McGregor
Background: Epidemiologic studies of skin and soft tissue infections (SSTIs) depend upon accurate case identification. Our objective was to evaluate the positive predictive value (PPV) of electronic medical record data for identification of SSTIs in a primary care setting.Methods: A validation study was conducted among primary care outpatients in an academic healthcare system. Encounters during four non-consecutive months in 2010 were included if any of the following were present in the electronic health record: International Classification of Diseases, Ninth Revision (ICD-9) code for an SSTI, Current Procedural Terminology (CPT) code for incision and drainage, or a positive wound culture. Detailed chart review was performed to establish presence and type of SSTI. PPVs and 95% confidence intervals (CI) were calculated among all encounters, initial encounters, and cellulitis/abscess cases.Results: Of the 731 encounters included, 514 (70.3%) were initial encounters and 448 (61.3%) were cellulitis/abscess cases. When the presence of an ICD-9 code, CPT code, or positive culture was used to identify SSTIs, 617 encounters were true positives, yielding a PPV of 84.4% [95% CI: 81.8–87.0%]. The PPV for using ICD-9 codes alone to identify SSTIs was 90.7% [95 % CI: 88.5–92.9%]. For encounters with cellulitis/abscess codes, the PPV was 91.5% [95% CI: 88.9–94.1%].Conclusions: ICD-9 codes may be used to retrospectively identify SSTIs with a high PPV. Broadening SSTI case identification with microbiology data and CPT codes attenuates the PPV. Further work is needed to estimate the sensitivity of this method.